Journal article
Refine
Has Fulltext
- yes (230)
Is part of the Bibliography
- yes (230)
Year of publication
Document Type
- Journal article (230) (remove)
Keywords
- Toxikologie (112)
- DNA damage (11)
- Adenosine receptors (8)
- DNA (5)
- DNA binding (5)
- Genotoxicity (5)
- oxidative stress (5)
- Adenylate cyclase (4)
- G proteins (4)
- Pharmakologie (4)
- heart failure (4)
- metabolism (4)
- micronuclei (4)
- Carcinogen (3)
- Carcinogenesis (3)
- Carcinogenicity (3)
- ERK1/2 (3)
- Enzyme induction (3)
- Medizin (3)
- Micronuclei (3)
- apoptosis (3)
- cytoskeleton (3)
- fluorescence resonance energy transfer (3)
- inflammation (3)
- mycotoxin (3)
- signal transduction (3)
- vitamin B6 (3)
- 1 (2)
- 5-Azacytidine (2)
- A1 adenosine receptors (2)
- Aflatoxin (2)
- Ames test (2)
- Carcinogens (2)
- DNA repair (2)
- Diethylstilbestrol (2)
- Dose response (2)
- Dose-response relationship (2)
- Electropermeabilization (2)
- Ernährung (2)
- Estrogen (2)
- G protein-coupled receptors (2)
- G-protein (2)
- GPCR (2)
- Hormone (2)
- N-formyl peptides (2)
- Pharmazie (2)
- RKIP (2)
- Radioligand binding (2)
- Rat (2)
- Reproductive toxicity (2)
- Salmonella/microsome assay (2)
- Silicones (2)
- actin (2)
- actinomycetes (2)
- adenosine receptors (2)
- barbiturates (2)
- biased signaling (2)
- biomedicine, general (2)
- calcium (2)
- cancer (2)
- cancer risk (2)
- cell biology (2)
- comet assay (2)
- cytokinins (2)
- differentiation (2)
- environmental health (2)
- familial DCM (2)
- heart (2)
- iPSC-cardiomyocytes (2)
- immunohistochemistry (2)
- in-vivo (2)
- insulin (2)
- kidneys (2)
- lymphocytes (2)
- mast cells (2)
- medicine (2)
- membrane skeleton (2)
- meningitis (2)
- nephrotoxicity (2)
- occupational medicine/industrial medicine (2)
- pharmacology/toxicology (2)
- phosphorylation (2)
- pneumolysin (2)
- pyridoxal phosphatase (2)
- rat brain membranes (2)
- risk assessment (2)
- therapy (2)
- transcription factors (2)
- yam (2)
- (Mouse L-cell) (1)
- (Rat brain membrane) (1)
- (Rat liver) (1)
- (Salmonella) (1)
- 18F-FDG (1)
- 2',7'-dichlorofluorescin (1)
- 2-Acetylaminofluorene (1)
- 2-Dichloroethane (1)
- 2-Dioxetane (1)
- 2-Generation reproduction (1)
- 3R (1)
- 4'-hydroxylation (1)
- 4-(p-nitrobenzyl)pyridine (1)
- 6-benzylaminopurine (1)
- 8-Hydroxy-deoxyguanosine (1)
- A(2B) receptors (1)
- A1 (1)
- A1 Adenosine receptors (1)
- A<sub>2</sub> Adenosine receptor (1)
- AMPK (1)
- A\(_{2A}\) adenosine receptor antagonist (1)
- Adenosine receptor (1)
- Adenosine receptor antagonists (1)
- Adenosinrezeptor (1)
- Aflatoxin B1 (1)
- Alkylation (1)
- Alzheimers disease (1)
- Amino acid composition (1)
- Amino acids (1)
- Anabolieagent (1)
- Aniline derivatives (1)
- Anthraquinone glycosides (1)
- Aryl hydrocarbon rnonooxygenase (1)
- Atria (1)
- B cells (1)
- BETA(2)-adrenergic receptor (1)
- Barbiturates (1)
- Barth syndrome (1)
- Benzefuran dioxetane (1)
- Benzefuran epoxide (1)
- Benzene (1)
- Benzo(a)pyrene-DNA binding (1)
- Berenil (1)
- Beta(1)-adrenergic receptor (1)
- Beta(2)-adrenergic receptor (1)
- Biomarkers (1)
- Bromodeoxyuridine labeling (1)
- C1q/TNF related protein (CTRP) (1)
- CIB1 (1)
- CRISPR Cas9 (1)
- CRISPR/Cas9 (1)
- CaMKII (1)
- Calcium (1)
- Cancer prevention (1)
- Carcinogen risk Individual susceptibili (1)
- Carcinogenic potency (1)
- Cardiac myocyte ; Beta-Receptor ; Muscarinic receptor ; cAMP ; G-protein ; Serum (1)
- Cell death and comet assay (1)
- Cell transformation (1)
- Chemical carcinogenesis (1)
- Chemotactic receptors (1)
- Choline deficiency (1)
- Chromosome aberration (1)
- Chromosome distribution (1)
- Chronic heart-failure (1)
- Covalent DNA binding (1)
- Covalent binding (1)
- Covalent binding index - Diethylstilbestrol (1)
- Cyclic AMP (1)
- Cytochrome b5 (1)
- DAMGO (1)
- DCM genetic background (1)
- DES (1)
- DNA Binding (1)
- DNA adduct . Repair endonuclease (1)
- DNA binching (1)
- DNA damage response (1)
- DNA metabolism (1)
- DNA methylation (1)
- DNA transfection (1)
- DNA-Binding (1)
- DNS-Schädigung (1)
- Dermatologie (1)
- Dietary process-related contaminants (1)
- Diisononyl phthalate (1)
- Dioscorea (1)
- Drug resistance (1)
- ERK signaling (1)
- Electric Field (1)
- Electrical breakdown (1)
- Electrophiles (1)
- Elektrofusion (1)
- Elektroporation (1)
- Emodin (1)
- Endogenous genotoxicity (1)
- Epoxide hydrolase (1)
- Estrone (1)
- Ethionine (1)
- Eukaryotic cell (1)
- External exposure assessment (1)
- FCS (1)
- FPG protein (1)
- FRET (1)
- Fabry Disease (FD) (1)
- Fischer 344 rats (1)
- Flow cytometry (1)
- Fluorescence resonance energy transfer (1)
- Friedreich’s ataxia (1)
- G protein coupled receptor (GPCR) (1)
- G protein-coupled receptor (1)
- G-protein coupled receptor (1)
- GABA-receptor complex (1)
- GPCRs (1)
- Gastric carcinogenesis (1)
- Gb3 and lyso-Gb3 biomarkers (1)
- Gene Transfer (1)
- Gene transfer (1)
- Genetic instability (1)
- Glutathione Stransferase (1)
- HIV infection (1)
- HPLC-MS/MS method (1)
- HeLa cells (1)
- High-throughput screening (1)
- Hoechst 33258 dye (1)
- Human platelets (1)
- Hybridoma (1)
- Immunization (1)
- Immunologie (1)
- In vitro toxicity testing (1)
- Inhalation (1)
- Ischemia/reperfusion (1)
- K + -channels (1)
- Kidneys (1)
- Kinetochore (1)
- Kinetochores (1)
- Krebs (1)
- Krebs <Medizin> (1)
- L5178Y cells (1)
- LTB4 receptor (1)
- Latrophilin (1)
- Leukocyte/endothelium interaction (1)
- Lung (1)
- MMQ cells (1)
- MammaJian mutagenicity test (1)
- Mechanism of action (1)
- Melanocortin 4 receptor (MC4R) (1)
- Melanocyte stimulating hormones MSH (1)
- Metabolism saturation (1)
- Microcirculation (1)
- Micronucleus formation (1)
- Micronucleus test (1)
- Mitosis (1)
- Molekularpharmakologie (1)
- Mutagenicity (1)
- Mutagenicity assay (1)
- Mutagens (1)
- Mutation assay (1)
- Myokarditis (1)
- N-methyl-N-nitrosourea (1)
- N1E 115 cells (1)
- Na\(_V\)1.8 (1)
- Neomycin Resistance (1)
- Nitrosation (1)
- Nitrosierung (1)
- OXPHOS (1)
- Oxidative stress (1)
- Oxygen radical (1)
- PBPK/PBTK model (1)
- PDE (1)
- PDE2 (1)
- PET (1)
- PKA (1)
- Phosphodiesterase (1)
- Photoaffinity labelling (1)
- Physiologically based kinetic models (1)
- Pointmutation (1)
- Prevalence (1)
- Prognostic impact (1)
- Prolactin (1)
- Protein binding (1)
- Protein coding (1)
- QIVIVE (1)
- Quantitative risk assessment (1)
- RBM20 mutations (1)
- ROS (1)
- Radiation inactivation (1)
- Radicals (1)
- Radioligand binding - 86Rb + -efflux (1)
- Radioligands (1)
- Radioligauds (1)
- Raman micro-spectroscopy (1)
- Rat Iiver microsomes (1)
- Rat liver peroxisome (1)
- Riot control agents (1)
- Risk assessment (1)
- Risk estimation (1)
- Risk-factors (1)
- SCN5a (1)
- ST-elevation myocardial infarction (1)
- Salmonella typhimurium (1)
- Sensitivity (1)
- Short-term Carcinogenicity Test (1)
- Short-term tests (1)
- Species differences (1)
- Spontaneous tumours (1)
- Stable Transformation (1)
- Streptomyces (1)
- T cells (1)
- TK6 cells (1)
- Target size (1)
- Theophylline (1)
- Thymidine glycol (1)
- Toluene (1)
- Toxin (1)
- Transfection (1)
- Transgenic mouse (1)
- Transgenie mice (1)
- Trenbolone (1)
- Tritiated Water (1)
- Unscheduled DNA synthesis (1)
- Uterine tumors (1)
- Valvular heart-desease (1)
- Venerologie (1)
- Volume distribution (1)
- Wachstumskonus (1)
- Water resources (1)
- Xanthines (1)
- Zelle (1)
- Zellskelett (1)
- [3H]PIA binding (1)
- absorption (1)
- actin cytoskeleton (1)
- activation (1)
- active zone (1)
- acute slices (1)
- adenine (1)
- adenosine (1)
- adenosine 3',5'-cyclic monophosphate (1)
- adenylate cyclase (1)
- adenylyl cyclase signaling cascade (1)
- adenylyl-cyclase isoforms (1)
- adhesion GPCR (1)
- adiponectin (1)
- adipose tissue (1)
- adult cardiac myocytes (1)
- adverse outcome pathway (1)
- adverse outcome pathway (AOP) (1)
- aflatoxin (1)
- ageing (1)
- agonists (1)
- aldosterone (1)
- alkylation (1)
- allelic variant (1)
- alternative methods (1)
- amine (1)
- amino acid (1)
- antagonists (1)
- anti-Parkinson agents (1)
- anti-inflammatory agents (1)
- antibacterial/antiviral drug (1)
- antibodies (1)
- antibody/autoantibody (1)
- antioxidants (1)
- aortocaval fistula model (1)
- aromatic amides (1)
- arrhythmia (1)
- arrhythmogenesis (1)
- assay (1)
- association (1)
- astrocytes (1)
- atopic eczema (1)
- atrial natriuretic peptide (1)
- avaliação de risco (1)
- bacterial meningitis (1)
- bariatric surgery (1)
- base excision repair (incision activity) (1)
- beta2-adrenoceptor knockout (1)
- beta3 CL 316,243 (1)
- binding (1)
- binding affinity (1)
- bioactive compounds (1)
- biofilms (1)
- biological techniques (1)
- biology (1)
- biomarker of exposure (1)
- biomarkers (1)
- blood coagulation factor XIII (1)
- blood plasma (1)
- blood pressure (1)
- blood samples (1)
- bone marrow (1)
- brain damage (1)
- brain membranes (1)
- cAMP (1)
- calcitonin gene-related peptide (1)
- calmodulin (1)
- carcinogen (1)
- cardiac hypertrophy (1)
- cardiac magnetic resonance imaging (1)
- cardiac myocyte ; muscarinic K current ; G-protein ; Albumin ; serum (1)
- cardiac remodelling (1)
- cardiomyocyte (1)
- cardiomyocytes (1)
- cardiovascular diseases (1)
- caveolin-1 (1)
- cell fate (1)
- cell fusion (1)
- cell proliferation (1)
- cell signalling (1)
- cell staining (1)
- chalcone (1)
- chemotactic receptors (1)
- chemotaxis (1)
- child health (1)
- cholesterol depletion (1)
- cholesterol-dependent cytolysin (1)
- chronic heart failure (1)
- chronic kidney disease (1)
- chronophin (1)
- cisplatin (1)
- classification (1)
- classification and labeling (1)
- clinical genetics (1)
- co-culture (1)
- coated vesicles (1)
- cognitive impairment (1)
- coherent anti-Stokes Raman scattering (CARS) microscopy (1)
- computational biophysics (1)
- conduction disease (1)
- conformational auto-epitope (1)
- conjugated mycotoxins (1)
- constitutive activity (1)
- contact lens (1)
- continuous (1)
- contractility (1)
- coumarin (1)
- coupled receptor (1)
- covalent binding (1)
- creatinine (1)
- crystal structure (1)
- cyclic AMP (1)
- cyclic dipeptide (1)
- cyclic nucleotides such as cyclic adenosine monophosphate (1)
- cyclic peptides/cyclopeptides (1)
- cyclic-AMP (1)
- cyclic-gmp (1)
- cyclopeptide therapy (1)
- cytochrome P450 2C9 (1)
- cytochrome P450s (1)
- cytome biomarkers (1)
- cytosol (1)
- cytotoxic (1)
- dCIRL (1)
- danio rerio (1)
- definition (1)
- dendritic spines (1)
- desensitization (1)
- detrusor muscle (1)
- developmental biology (1)
- diabetes (1)
- diagnosis (1)
- dialysis (1)
- dicyclohexyl phthalate (1)
- diet (1)
- dilated cardiomyopathy with ataxia (1)
- disrupting chemicals (1)
- disruptor endócrino (1)
- docking (1)
- domains (1)
- dormancy (1)
- down-regulation (1)
- drug (1)
- dunce (1)
- eccentric hypertrophy (1)
- ectodomain cleavage (1)
- efficient intervention points (1)
- endocrine disruptor (1)
- endogenous (1)
- energy-transfer (1)
- environmental phenols (1)
- enzyme-linked immunoassays (1)
- epigenetics (1)
- estrogen receptor (1)
- ethanol (1)
- etoposide (1)
- eugenol (1)
- exposição humana (1)
- exposure (1)
- fatty liver (1)
- fentanyl (1)
- fetal testis (1)
- fluorescence (1)
- fluorescence correlation spectroscopy (1)
- fluorescence detection (1)
- fluorescence imaging (1)
- fluorescence recovery after photobleaching (1)
- fluorescent probes (1)
- food contact materials (1)
- food safety (1)
- food security (1)
- formyl peptides (1)
- functional clustering (1)
- fungi (1)
- gastrointestinal cancer (1)
- general medicine (1)
- genetics (1)
- genomic damage (1)
- genotoxic (1)
- genotoxicity (1)
- genotypes (1)
- glucuronide (1)
- glutamate (1)
- glycolytic flux control (1)
- gravidez (1)
- growth cone (1)
- hA<sub>3</sub>AR (1)
- hOCT1 (1)
- haematopoietic stem cells (1)
- haloacid dehalogenase (1)
- haloacid dehalogenase-type phosphatase (1)
- healing and remodelling processes (1)
- hiPSC-CM (1)
- hidden mycotoxins (1)
- histamine release (1)
- homeostasis (1)
- homodimerization (1)
- hormone receptors (1)
- human (1)
- human A(3) (1)
- human biomonitoring (1)
- human exposure (1)
- human lung (1)
- hypertension (1)
- hypertonic solution (1)
- identification (1)
- impact pharmacogenetics (1)
- in vivo (1)
- indolylpyrimidylpiperazines (1)
- induced pluripotent stem cell cardiomyocytes (1)
- induced pluripotent stem cells (1)
- inflammatory diseases (1)
- insulin signaling (1)
- internalization (1)
- international union (1)
- intracellular loop (1)
- intrinsic metabolism (1)
- ionic look (1)
- ischemic stroke (1)
- isoproterenol (1)
- key event relationship (1)
- kinases (1)
- laminopathy (1)
- lamivudine (1)
- late Na\(^+\) current (I\(_{NaL}\)) (1)
- legislation (1)
- life (1)
- ligand binding (1)
- lipid rafts (1)
- lipidomics (1)
- listeriolysin O (1)
- live imaging (1)
- liver (1)
- liver microsomes (1)
- living vells (1)
- long-read sequencing (1)
- lovastatin (1)
- lysosomal disruption (1)
- lysosomal storage disorders (1)
- mTOR-inhibitor RAD-001 (1)
- maintenance of genomic integrity (1)
- major depression (1)
- male rats (1)
- mammalian genomics (1)
- marine sponges (1)
- masked mycotoxins (1)
- matrix metalloproteinase (1)
- maturation strategies (1)
- mechanotransduction (1)
- membrane (1)
- membrane transporters (1)
- memory B cells (1)
- mercapturic acid (1)
- metabotropic signalling (1)
- micronucleus test (1)
- microvessel permeability (1)
- mild (1)
- mitochondria (1)
- mitochondrial DNA polymerase γ (1)
- mitochondrial cardiomyopathy (1)
- mitotic disturbance (1)
- modelo PBPK/PBTK (1)
- modified mycotoxins (1)
- molecular biology (1)
- molecular dynamics (1)
- molecular modeling (1)
- molecular modelling (1)
- monogenetic cardiomyopathies (1)
- mortality (1)
- motor performance (1)
- mouse lymphoma L5178Y (1)
- mouse models DNA damage (1)
- mucosa (1)
- multivariate data analysis (1)
- mutagen (1)
- mutagenicity (1)
- mutant mice (1)
- mutation triggers (1)
- mycotoxin derivates (1)
- mycotoxin metabolites (1)
- mycotoxins (1)
- myocarditis (1)
- n-hexyl phthalate (1)
- nanopore (1)
- natural (1)
- neocortex (1)
- neurodegenerative diseases (1)
- neuronal dendrites (1)
- neurons (1)
- neuropsychiatric diseases (1)
- neurotransmitter biosynthesis (1)
- neutrophils (1)
- nitric-oxide (1)
- nitrosation (1)
- nitroso compound (1)
- no (1)
- nutritional composition (1)
- o-Chlorobenzylidene malononitrile (1)
- obesity (1)
- occurrence (1)
- ochratoxin A (1)
- octopamine (1)
- opioid ligands (1)
- optimal drug combination (1)
- optimal drug targeting (1)
- optimal pharmacological modulation (1)
- optimal treatment strategies (1)
- organ toxicity (1)
- parathyroid hormone 1 receptor (1)
- partial agonists (1)
- performance liquid-chromatography (1)
- peripheral nerve (1)
- peripheral-blood lymphocytes (1)
- personalized treatment (1)
- perspectives (1)
- pharmacogenetics (1)
- phosphoglycolate phosphatase (1)
- phosphoinositides (1)
- photoaffinity labelling (1)
- plasma membrane (1)
- poly(ADP-ribosyl)ation (1)
- pore formation (1)
- pore-forming toxin (1)
- positron emission tomography (1)
- potent (1)
- pregnancy (1)
- primary aromatic amine (1)
- protein (1)
- protein alkylation (1)
- protein design (1)
- protein-coupled receptors (1)
- protein-coupled-receptors (1)
- psoriasis (1)
- psychiatric disorders (1)
- purine derivatives (1)
- pyrrolizidine alkaloids (1)
- quantitative assessments (1)
- radiation (1)
- radii (1)
- radioligand (1)
- radioligand binding (1)
- rat pheochromocytoma cells (1)
- receptor binding (1)
- receptor pharmacology (1)
- receptor solubilization (1)
- receptor-G protein coupling (1)
- receptor-G protein coupling. (1)
- receptors (1)
- regulation (1)
- relaxation (1)
- reproductive and developmental toxicity (1)
- resveratrol (1)
- risk-assesment (1)
- sensory physiology (1)
- serum (1)
- sex (1)
- sexual development (1)
- signaling microdomain (1)
- simulated digestion (1)
- single-molecule microscopy (1)
- solid-phase extraction (1)
- solubilization (1)
- sponges (1)
- spontaneously hypersensitive-rats (1)
- staphilococci (1)
- statins (1)
- stomach (1)
- streptomyces (1)
- sub-Saharan Africa (1)
- subtypes (1)
- sugars (1)
- synapses (1)
- synaptic plasticity (1)
- tMCAO (1)
- tandem mass-spectrometry (1)
- targets (1)
- testosterone production (1)
- therapeutic potential (1)
- thyroid hormone (1)
- tissue (1)
- tolbutamide substrate (1)
- toxicocinética (1)
- toxicokinetics (1)
- toxicology (1)
- trans-Golgi network (1)
- transgenic animals (1)
- triazolotriazine derivatives (1)
- tuber (1)
- ultrastructure (1)
- urea (1)
- uremic toxins (1)
- variocosities (1)
- vitamin-D-receptor (1)
- volume overload (1)
- warfarin polymorphisms (1)
- weight of evidence (1)
- yellow fluorescent protein (1)
- µ-Opioid receptor (1)
- β-adrenergic receptors (1)
- β1-adrenoceptor/β1-adrenergic receptor (1)
- βAR (1)
- γ-Aminobutyric acid (GABA) (1)
Institute
- Institut für Pharmakologie und Toxikologie (230) (remove)
Sonstige beteiligte Institutionen
A\(_1\) adenosine receptors in coated vesicles have been characterized by radioligand binding and photoaflinity labelling. Saturation experiments with the antagonist 8-cyclopentyl-1 ,3-[\(^3\)H]dipropyl-xanthine ([\(^3\)H]DPCPX) gave a Kdvalue of 0.7 nM and a Bmax value of 82± 13 fmol/mg protein. For the highly A\(_1\)-selective agonist 2-chloro-N\(^6\)-[\(^3\)H]cyclopentyladenosine ([\(^3\)H]CCPA) a Kd value of 1.7 nM and a Bmax value of 72 ± 29 fmol/mg protein was estimated. Competition of agonists for [\(^3\)H]DPCPX binding gave a pharmacological profile with R-N\(^6\)-phenylisopropyladenosine (R-PIA) > CCPA > S-PIA > 5'-N-ethylcarboxamidoadenosine (NECA), which is identical to brain membranes. The competition curves were best fitted according to a two-site model, suggesting the existence of two affinity states. GTP shifted the competition curve for CCP A to the right and only one affinity state similar to the low affinity state in the absence of GTP was detected. The photoreactive agonist 2-azido-N\(^6\)- \(^{125}\)I-p-hydroxyphenylisopropyladenosine ([\(^{125}\)I]AHPIA) specifically labelled a single protein with an apparent molecular weight of 35,000 in coated vesicles, which is identical to A\(_1\) receptors labelled in brain membranes. Therefore, coated vesicles contain A\(_1\) adenosine receptors with similar binding characteristics as membrane-bound receptors, including GTP-sensitive high-affinity agonist binding. Photoaffinity labelling data suggest that A\(_1\) receptors in these vesicles are not a processed receptor fonn. These results confirm that A\(_1\) receptors in coated vesicles are coupled to a G-protein, and it appears that the A\(_1\) receptor systems in coated vesicles andin plasma membranes are identical.
Reduction of postischemic leukocyte-endothelium interaction by adenosine via A\(_2\) receptor
(1992)
The adhesion of leukocytes to the endothelium of postcapillary venules hallmarks a key event in ischemia-reperfusion injury. Adenosine has been shown to protect from postischemic reperfusion injury, presumably through inhibition of postischemic leukocyte-endothelial interaction. This study was performed to investigate in vivo by which receptors the effect of adenosine on postischemic leukocyte-endothelium interaction is mediated. The hamster dorsal skinfold model and fluorescence microscopy were used for intravital investigation of red cell velocity, vessel diameter, and leukocyte-endothelium interaction in postcapillary venules of a thin striated skin muscle. leukocytes were stained in vivo with acridine orange (0.5 mg kg\(^{-1}\) min\(^{-1}\) i.v. ). Parameters were assessed prior to induction of 4 h ischemia to the muscle tissue and 0.5 h, 2 h, and 24 h after reperfusion. ·Adenosine, the adenosine A1-selective agonist 2-chloro-N\(^6\) -cyclopentyladenosine (CCPA), the Arselective agonist CGS 21,680, the non-selective adenosine receptor antagonist xanthine amine congener {XAC), and the adenosine uptake blocker S-(p-nitrobenzyl)-6-thioinosine (NBTI) were infused viajugular vein starting 15 min priortorelease of ischemia until 0.5 h after reperfusion. Adenosine and CGS 21,680 significantly reduced postischemic leukocyte-endothelium interaction 0.5 h after reperfusion (p< 0.01), while no inhibitory effect was observed with CCPA. Coadministration of XAC blocked the inhibitory effects of adenosine. Infusion of NBTI alone effectively decreased postischemic leukocyte-endothelium interaction. These findings indicate that adenosine reduces postischemic leukocyte-endothelium interaction via A\(_2\) receptor and suggest a protective role of endogenous adenosine during ischemia-reperfusion.
In the search for more selective A2-receptor agonists and on the basis that appropriate substitution at C2 is known to impart selectivity for A\(_2\) receptors, 2-alkynyladenosines 2a-d were resynthesized and evaluated in radioligand binding, adenylate cycla.se, and platelet aggregation studies. Binding of [\(^3\)H]NECA to A\(_2\) receptors of rat striatal membranes was inhibited by compounds 2a-d with K\(_i\) values ranging from 2.8 to 16.4 nM. 2-Alkynyladenosines also exhibited high-affmity binding at solubilized A\(_2\) receptors from human platelet membranes. Competition of 2-alkynyladenosines 2a-d for the antagonist radioligand [\(^3\)H]DPCPX and for the agonist [\(^3\)H]CCPA gave K\(_i\) values in the nanomolar range, and the compounds showed moderate A\(_2\) selectivity. In order to improve this selectivity, the correaponding 2-alkynyl derivatives of adenosine-5'-N-ethyluronamide 8a-d were synthesized and tested. A\(_1\) expected, the 5'-N-ethyluronamide derivatives retained the A\(_2\) affinity whereas the A\(_1\) affinity was attenuated, resulting in an up to 10-fold increase in A\(_2\) selectivity. A similar patternwas observed in adenylate cyclase assays andin platelet aggregation studies. A 30- to 45-fold selectivity for platelet A\(_2\) receptors compared to A\(_1\) receptors was found for compounds 8a-c in adenylate cyclase studies.
Photoaffinity-labeled N-formyl chemotactic peptide receptors from human neutrophils solubilized in octyl glucoside exhibit two forms upon sucrose density gradient sedimentation, with apparent Sedimentation coefficients of approximately 4 and 7 S. Tbe 7 S form can be converted to the 4 S form by guanosine 5' -0- (3-thiotriphosphate) (GTP-yS) with an EC&o of -20 nM, suggesting that the 7 S form may represent a physical complex of the receptor with endogenous G protein (Jesaitis, A. J., Tolley, J. 0., Bokoch, G. M., and Allen, R. A. (1989) J. Cell Biol. 109, 2783-2790). To probe the nature of the 7 S form, we reconstituted the 7 S form from the 4 S form by adding purified G protein. The 4 S form, obtained by solubilizing GTP-yS-treated neutrophil plasma membranes, was incubated with purified (>95%) G. protein from bovine brain (containing both G\(_{ia1}\) and G\(_{ia2}\)) or with neutrophil G protein (G\(_a\)), and formation of the 7 S complex was analyzed on sucrose density gradients. The EC\(_{50}\) of 7 S complex formation induced by the two G proteins was 70 \(\pm\) 25 and 170 \(\pm\) 40 DM for G\(_a\) and G\(_1\), respectively. No complexation was measurable when bovine transducin (G\(_t\)) was used up to 30 times the EC\(_{50\) for G\(_a\). The EC\(_{50}\) for G\(_t\) was the same for receptors, obtained from formyl peptide-stimulated or unstimulated cells. The addition of 10 \(\mu\)M GTP-yS to the reconstituted 7 S complex caused a complete reversion of the receptor to the 4 S form, and anti-G\(_1\) peptide antisera immunosedimented the 7 S form. ADP-ribosylation of Gt prevented formation of the 7 S form even at 20 times the concentration of unribosylated G. normally used to attain 50% conversion to the 7 S form. These observations suggest that the 7 S species is a pbysical complex containing N-formyl chemotactic peptide receptor and G protein.
The mechanism of the therapeutic and prophylactic effects of carbamazepine (CBZ) in affective psychoses is unknown but may in part be related to the potent competitive interaction of CBZ with adenosine-binding sites in the brain. The antioonvulsant and sedative properties of CBZ are reminiscent of the effects evoked by adenosine-agonists and contrast sharply with the opposite aclions of adenosine-antagonists like caffeine. However. indirect evidence suggests an antagonist- rather than an agonist-like activity of CBZ at adenosi11e-receptors. We have used various model systems, in which adenosine receptor subtypes mediate different second messenger-responses, to investigate this apparent paradox. CBZ was found to antagonize the A\(_1\) receptor-mediated inhibition of cydic AMP accumulation in cultured astroblasts and in GH3-cells. Furthermore, CBZ also inhibits the adenosine-induced increase in the level of cyclic AMP in cultured astroblasts, which is mediated by low-affinity A\(_{2b}\)-receptors. ln contrast, CBZ does not block the inhibition elicited by adenosine-agonists of the agonist-induced increased formation of inositolphosphates in human neutrophils, which is mediated by high-affinity A\(_{2a}\)-receptors. The specific antagonism by CBZ of A\(_1\)- but not of high-affinity A\(_{2a}\)-receptors was further supported by binding experiments using rat brain membranes. These results suggest tbat the paradox of CBZ's antagonistic effects at adenosine-receptors might be at least partially reconciled by a selective antagonistic action of CBZ at A\(_1\)recertors but not at high-affinity A\(_{2a}\)-receptors.
Radioligand binding to A\(_1\) adenosine receptors at brain membranes from seven species was investigated. The antagonist 8-cyclopentyl-1 ,3-[\(^3\)H]dipropylxanthine ([\(^3\)H]DPCPX) bound with affinities between 0.17 nM in sheep brain and 2.1 nM in guinea pig brain. Competition of several antagonists for [\(^3\)H]DPCPX binding showed that the most potent compounds were DPCPX with K\(_i\) values of 0.05 nM in bovine brain and 1.1 nM in guinea pig brain and xanthine amine congener (XAC) with K\(_i\) values of 0.03 nM in bovine brain and 5.5 nM in guinea pig brain. The differences in affinity of the agonist radio Iigand 2-chloro-N\(^6\) -[\(^3\)H]cyclopen tyladenosine ([\(^3\)H]CCP A) were less pronounced, rauging from a K\(_D\) value of 0.12 nM (hamster brain) to 0.42 nM (guinea pig brain). Agonist competition for [\(^3\)H]DPCPX binding of photoaffinity labelling, however, exhibited marked species differences. N-Ethylcarboxamidoadenosine (NECA) and S-N\(^6\)-phenylisopropyladenosine (S-PIA) showed 20 to 25-fold different K\(_D\) values in different species. NECA had a particularly high affinity in guinea pig brain and was only two-fold less potent than R-PIA. Thus, the difference from the "classical" A\(_1\) receptor profile (R-PIA > -NECA > S-PIA) is not sufficient to speculate that A\(_1\) receptor subtypes may exist that are coupled to different effector systems. Our data show that these difference can easily be explained by species differences.
Active neuropeptide Y receptors were solubilized from rabbit kidney membranes using the zwitterionic detergent 3-[ (3-cholamidopropy l)dimethylammonio ]- 1-propanesulfonic acid (CHAPS). In membrane fragmentsandsoluble extracts neuropeptide Y bindingwas time dependent, saturable, reversible, and of high affinity. Scatchard analysis of equilibrium binding data indicated a single class of binding sites with respective Kn and Bmax values of 0.09 nM and 530 fmol/mg of protein for the membrane-bound receptors and 0.10 nM and 1585 fmol/mg of protein for the soluble receptors. Neuropeptide Y bindingwas specifically inhibited by the nonhydrolyzable GTP analog guanosine 5' -0- (3-thiotripbosphate) in a concentration-dependent manner, with IC\(_{50}\) values of 28 and 0.14 \(\mu\)M for membrane- bound and soluble receptors, respectively, suggesting that neuropeptide Y receptors are functionally coupled to GTP-binding regulatory proteins. CrossHoking studies were performed with the heterobifunctional N-hydroxysuccinimidyl-4-azidobenzoate and the monofunctional neuropeptide Y derivative, azidobenzoyl and led to the identification of a 100 kDa peptide that should represent the covalently labeled neuropeptide Y receptor.
The effects of guanine nucleotides on binding of 8-cyclopentyl-1,3-[\(^3\)H]dipropylxanthine [\(^3\)H]DPCPX), a highly selective A\(_1\) adenosine receptor antagonist, have been investigated in rat brain membranes and solubilized A\(_1\) receptors. GTP, which induces uncoupling of receptors from guanine nucleotide binding proteins, increased binding of [\(^3\)H]DPCPX in a concentration-dependent manner. The rank order of potency for different guanine nucleotides for increasing [\(^3\)H]DPCPX bindingwas the same as for guanine nuc1eotide-induced inhibition of agonist binding. Therefore, a role for a guanine nucleotide binding protein, e.g., G\(_i\), in the regulation of antagonist binding is suggested. This was confirmed by inactivation ofGi by N-ethylmaleimide (NEM) treatment of membranes, which resulted in an increase in [\(^3\)H]DPCPX binding similar to that seen with addition of GTP. Kinetic and equilibrium binding studies showed that the GTP- or NEM-induced increase in antagonist binding was not caused by an affinity change of A\(-1\) receptors for [\(^3\)H]DPCPX but by an increased Bmu value. Guanine nucleotides had similar effects on membrane-bound and solubilized receptors, with the effects in the solubilized system being more pronounced. In the absence of GTP, when rnost receptors are in a high-affinity state for agonists, only a few receptors are labeled by [\(^3\)H]DPCPX. It is suggested that [\(^3\)H]DPCPX binding is inhibited when receptors are coupled to G\(_i\). Therefore, uncoupling of A\(_1\) receptors from G\(_i\) by guanine nucleotides or by inactivation of G\(_i\) with NEM results in an increased antagonist binding.
Key Words: Adenosine receptors-8 -Cyclopentyl-1,3-eH]dipropylxanthine-Antagenist binding-Guanine nucleotide effects. Klotz K.-N. et al. Guanine nucleotide etfects on 8-cyclopentyl-1 ,3-eH]dipropylxanthine binding to membrane-bound and solubilized A1 adenosine receptors of rat brain. J. Neurochem. 54, 1988-1994 (1990).
1 Adenosine and its metabolically stable analogue N.etbyl-carboxamidoadenosine (NECA) enhance histamine release from rat peritoneal mast cells when tbese are stimulated by calciummobilizing agents. NECA and adenosine shift the concentration-response curve of tbe calcium ionophore A23187 to lower concentrations. 2 The potencies of NECA or adenosinein enhancing A23187-induced histamine release are dependent on the Ievel of stimulated release in tbe absence of adenosine analogues. At high Ievels of release their potencies are up to 20 times higher than at low Ievels. Consequently, averaged concentration-response curves of adenosine and NECA for enhancing bistamine release are shallow. 3 The adenosine transport blocker S-(p-nitrobenzyl)-6-thioinosine (NBTI) has no effect by itself at low Ievels of stimulated histamine release, but abolishes the enhancing effect of adenosine. At high Ievels of release, however, NBTI alone enhances the release of histamine. 4 lt is concluded that adenosine and calcium reciprocally enhance the sensitivity of the secretory processes to the effects of the other agent. The Ievels of intracellular adenosine obtained by trapping adenosine inside stimulated mast cells are sufficient to enhance histamine release substantially, suggesting that this effect may play a physiological and pathophysiological role.